Abliva AB Interim Report January – March 2023
Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Press releases
Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 5, 2023, held its Annual General Meeting (“AGM”). A summary of the resolution follows.
Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023
The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee's proposal for the election of Board members was […] ...
Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the drug candidate NV354 has ...
Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Friday, 5 May 2023 at Medicon Village, Scheeletorget ...
Abliva AB Publishes 2022 Annual Report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolutions follows.
Abliva AB Year-End Report January – December 2022
A successful financing enabled the start of the FALCON study with KL1333
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 11.00 a.m. on Wednesday 8 March 2023 at ...
Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings
The Nomination Committee of Abliva AB proposes that Dr. Edwin Moses be elected as a new Board member of the Company through a shareholder vote at the EGM on March 8, 2023. Dr. Moses, who has over 30 y ...
Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the granting of a composition of ...
Abliva Appoints Dag Nesse as Vice President of Clinical Operations
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the appointment of Dag Nesse as V ...